1. Home
  2. APYX vs MGNX Comparison

APYX vs MGNX Comparison

Compare APYX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apyx Medical Corporation

APYX

Apyx Medical Corporation

HOLD

Current Price

$3.68

Market Cap

128.0M

Sector

Health Care

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.91

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APYX
MGNX
Founded
1982
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.0M
115.8M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
APYX
MGNX
Price
$3.68
$2.91
Analyst Decision
Strong Buy
Hold
Analyst Count
4
5
Target Price
$6.50
$3.40
AVG Volume (30 Days)
123.2K
1.5M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
19.40
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
$11.92
N/A
Revenue Next Year
$10.08
$16.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$0.99
52 Week High
$4.50
$3.50

Technical Indicators

Market Signals
Indicator
APYX
MGNX
Relative Strength Index (RSI) 49.59 56.75
Support Level $3.27 $1.46
Resistance Level $4.29 $3.50
Average True Range (ATR) 0.26 0.22
MACD 0.00 -0.05
Stochastic Oscillator 37.35 34.55

Price Performance

Historical Comparison
APYX
MGNX

About APYX Apyx Medical Corporation

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: